Loading…
Loading…
Unique MRI Study Shows How the Combination Exerts its Effect VANCOUVER, BC – TheNewswire - May 1, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of a study that further validates the immune response mechanism from a combination of its maveropepimut-S (MVP-S) immunotherapeutic vaccine combined with a checkpoint inhibitor and low dose intermittent cyclophosphamide in ovarian cancer. Led by Dr Kimberly Brewer of the IWK Health Center and Associate Professor, Faculty of Medicine-Dalhousie University, the study is entitled “MRI of Combination Immunotherapy in an Epithelial Ovarian Cancer Preclinical Model” and is published in the April 2026 edition of Nature/NPJ Imaging.
VANCOUVER, BC, April 28 2026 - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, its related management's discussion and analysis, and the Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. As a result of the delay in filing the Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2026, its related management's discussion and analysis, and related filings (collectively, the “ Interim Filings ”). Under National Instrument 51-102, the Interim Filings were required to be made not later than April 1, 2026.
VANCOUVER, BC, April 27th, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0) today announced the acceptance of an abstract related to the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of BioVaxys' MVP-S with pembrolizumab (Keytruda™) and cyclophosphamide in patients with recurrent epithelial ovarian cancer for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, May 29th-June 6th, 2026. With over 44,000 expected attendees, including oncologists, researchers, and pharmaceutical professionals, the ASCO Annual Meeting is a top-tier global oncology conference, and is recognized as one of the most significant, high-visibility events for clinical trials, research, and oncology innovation. All accepted ASCO abstracts are published online as a supplement to the Journal of Clinical Oncology (JCO),
VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. The Company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to complete the Annual Filings, which will be filed as soon as possible. As previously stated, subject to current conditions remaining the same, the Company remains confident in its ability to complete the Annual Filings by April 28, 2026.
VANCOUVER, BC, March 31, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. The Company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to complete the Annual Filings, which will be filed as soon as possible. As previously stated, subject to current conditions remaining the same, the Company remains confident in its ability to complete the Annual Filings by April 28, 2026.
VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. The Company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to complete the Annual Filings, which will be filed as soon as possible. As previously stated, subject to current conditions remaining the same, the Company remains confident in its ability to complete the Annual Filings by April 28, 2026.
Vancouver, BC – TheNewswire - March 3rd, 2026 – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) announces that it was unable to file its annual financial statements, management's discussion and analysis and the required certifications for the year ended October 31, 2025 (the “ Annual Filings ”) on or before the prescribed filing deadline of February 28, 2026 (the “ Annual Filing Deadline ”). The Company and the auditor have been diligently working to complete the Annual Filings, however, the Company was not able to make the required filings by the Annual Filing Deadline. The primary contributing factor to the delay was a late start to the audit as a result of the Company making changes to its accounting systems and processes. The Company believes that the audit will be completed by April 28, 2026, with the annual filings to be completed as soon as possible thereafter.
Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer VANCOUVER, BC – TheNewswire - January 29, 2026 / TheNewswire / - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) (“BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, today announced positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) in combination with pembrolizumab and low-dose cyclophosphamide in patients with advanced or metastatic bladder cancer. These results build on the Company's recent Phase 1B/2 data in advanced ovarian cancer and further validate the potential of MVP-S to enhance checkpoint inhibitor activity across multiple solid tumor indications.
No recent filings indexed.